Molbio Diagnostics share price hits 20% upper circuit, jumps 87% from IPO price

Molbio Diagnostics shares hit the 20% upper circuit limit on September 10, 2026, reaching an all-time high of ₹1,509.70. This surge follows a strong financial performance in the first quarter of fiscal 2027, where the company reported a profit of ₹52.74 crore. The rally is largely driven by a significant increase in the volume of its Truenat test kits, which signals robust demand for its diagnostic solutions.

For investors, this move highlights Molbio’s strong market position and its ability to capitalize on the growing need for diagnostic testing. The sharp jump in stock price, which is now 87% higher than its IPO price, reflects the market’s positive sentiment towards the company’s growth trajectory. However, given the rapid price appreciation, investors should monitor the stock for any volatility and keep an eye on future quarterly results to gauge the sustainability of this momentum.

Moving forward, the key focus will be on Molbio’s ability to maintain its growth momentum and expand its market share. Investors should watch for updates on new product launches, expansion into new geographies, and the overall demand for its diagnostic services. Keeping an eye on the company’s quarterly earnings will be crucial to understanding whether the current rally is supported by strong fundamentals or if it is driven by market sentiment alone.